back to US directory
us clinical guidance

Lyme disease prevention, diagnosis and treatment

North American tick-bite risk assessment, erythema migrans diagnosis, staged testing, treatment boundaries and organ-specific escalation.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Patients in North America with an attached tick, compatible erythema migrans or possible neurologic, cardiac or rheumatologic Lyme disease. The AAN/ACR/IDSA guideline excludes comprehensive babesiosis and rickettsial management. Geographic exposure, tick species, attachment and disease manifestation must be assessed rather than treating every bite or nonspecific symptom as Lyme disease.
sources for this section:AAN/ACR/IDSA Lyme 2020

The Bottom Line

  • Remove an attached tick promptly with fine-tipped tweezers and do not burn it or apply petroleum or irritating chemicals; prevention counseling should address repellents, clothing and post-exposure skin checks.
  • Do not test an asymptomatic patient after a tick bite and do not test the tick for Borrelia to predict human infection; either result can mislead subsequent care.
  • Offer prophylaxis only for an identified high-risk Ixodes bite when presentation is within the guideline window and attachment, endemic geography and lack of contraindication meet all criteria.
  • Diagnose a typical erythema migrans lesion clinically after credible exposure; use validated antibody testing for other compatible manifestations while accounting for the early seronegative window and background antibodies.
sources for this section:AAN/ACR/IDSA Lyme 2020

Practical clinical workflow

1
Establish where and when exposure occurred, tick appearance, attachment duration, engorgement, removal time, evolving rash, fever, facial weakness, meningitic symptoms, palpitations, syncope, joint swelling and co-infection clues.
2
For a typical expanding erythema migrans lesion, select a recommended oral regimen based on age, pregnancy, allergy, tolerability, sun exposure and possible co-infection; avoid waiting for insensitive early serology.
3
For atypical rash or extracutaneous disease, order the source-supported serologic strategy and targeted ECG, cerebrospinal-fluid or joint evaluation only when the specific presentation warrants it.
4
Document objective response and reassess persistent symptoms for reinfection, treatment failure, another tick-borne infection or a non-Lyme diagnosis rather than automatically extending antimicrobial treatment.
sources for this section:AAN/ACR/IDSA Lyme 2020

Safety boundaries and escalation

  • Syncope, chest pain, dyspnea, marked bradycardia or suspected high-grade atrioventricular block requires urgent cardiac monitoring and treatment rather than outpatient reassurance.
  • Meningitis, painful radiculoneuritis, evolving focal deficit, encephalomyelitis or severe facial palsy with neurologic features requires prompt organ-specific evaluation and specialist input.
  • A hot swollen joint requires confirmation of the diagnosis and exclusion of bacterial septic arthritis; Lyme arthritis and septic arthritis can overlap clinically, particularly in children.
  • Do not give additional antibiotics for persistent nonspecific fatigue, pain or cognitive symptoms without objective evidence of reinfection or treatment failure; prolonged therapy can cause serious harm.
sources for this section:AAN/ACR/IDSA Lyme 2020

Localization

This is a North American AAN/ACR/IDSA pathway. State reporting rules and public-health maps should inform exposure assessment, while local emergency and specialist pathways determine disposition for cardiac, neurologic and arthritic disease.
sources for this section:AAN/ACR/IDSA Lyme 2020

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme DiseaseDOI 10.1093/cid/ciaa1215 路 published 2020-11-30 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.